
    
      SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study
      (tumor registry platform) with the purpose to record information on the antineoplastic
      treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany.
      The registry will follow patients for up to two years. It will identify common therapeutic
      sequences and changes in the treatment of the disease. At inclusion, data in patient
      characteristics, comorbidities, tumor characteristics and previous treatments are collected.
      During the course of observation data on all systemic treatments, radiotherapies, surgeries,
      and outcome are documented.

      Health-related quality of life (HRQoL) will be evaluated for up to two years.
    
  